Last reviewed · How we verify
Apacil (AMINOSALICYLIC ACID)
Apacil (aminosalicylic acid) is a small molecule drug originally developed by Consolidated Midland, which remains its current owner. It targets tyrosine-protein phosphatase non-receptor type 1 and is used to treat acute and pulmonary tuberculosis. Apacil is classified as an aminosalicylic acid and was FDA-approved in 1950. It is now off-patent and has a generic manufacturer. As an off-patent drug, it is no longer protected by active patents.
At a glance
| Generic name | AMINOSALICYLIC ACID |
|---|---|
| Sponsor | Consolidated Midland |
| Drug class | aminosalicylic acid |
| Target | Tyrosine-protein phosphatase non-receptor type 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
- Acute tuberculosis
- Pulmonary tuberculosis
Common side effects
Key clinical trials
- Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis (NA)
- Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease (PHASE2,PHASE3)
- Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis. (NA)
- Desloratadine in Patients With Ulcerative Colitis (PHASE2)
- Pentoxifylline in Patients With Ulcerative Colitis (PHASE2)
- Confirmatory Clinical Study in Active Ulcerative Colitis (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apacil CI brief — competitive landscape report
- Apacil updates RSS · CI watch RSS
- Consolidated Midland portfolio CI